California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Benbow, Christopher
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Completed
3
464
Europe, US, RoW
SEP-363856 75mg, SEP-363856 100mg, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
06/23
06/23
NCT05628103: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Completed
3
101
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
04/24
04/24
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Terminated
3
463
Europe, US, RoW
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
11/23
11/23
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Completed
1
31
US
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
09/23
09/23
NCT05463770: A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Completed
1
15
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
08/23
08/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Benbow, Christopher
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Completed
3
464
Europe, US, RoW
SEP-363856 75mg, SEP-363856 100mg, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
06/23
06/23
NCT05628103: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Completed
3
101
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
04/24
04/24
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Terminated
3
463
Europe, US, RoW
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
11/23
11/23
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Completed
1
31
US
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
09/23
09/23
NCT05463770: A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Completed
1
15
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
08/23
08/23

Download Options